Is Sucampo Pharmaceuticals, Inc. (SCMP) Going to Burn These Hedge Funds?

Consequently, key money managers were breaking ground themselves. HBK Investments, managed by David Costen Haley, assembled the most valuable position in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). HBK Investments had $3.1 million invested in the company at the end of the quarter. Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital also made a $0.4 million investment in the stock during the quarter. The other funds with new positions in the stock are Richard Driehaus’s Driehaus Capital, Glenn Russell Dubin’s Highbridge Capital Management, and Ken Griffin’s Citadel Investment Group.

Let’s now take a look at hedge fund activity in other stocks similar to Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). We will take a look at QLogic Corporation (NASDAQ:QLGC), MTS Systems Corporation (NASDAQ:MTSC), Gener8 Maritime Inc (NYSE:GNRT), and Atara Biotherapeutics Inc (NASDAQ:ATRA). This group of stocks’ market values are closest to SCMP’s market value.

As you can see these stocks had an average of 17.5 hedge funds with bullish positions and the average amount invested in these stocks was $257 million. That figure was $48 million in SCMP’s case. QLogic Corporation (NASDAQ:QLGC) is the most popular stock in this table. On the other hand Atara Biotherapeutics Inc (NASDAQ:ATRA) is the least popular one with only 11 bullish hedge fund positions. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) is not the most popular stock in this group but hedge fund interest is still above average. This is a slightly positive signal but we’d rather spend our time researching stocks that hedge funds are piling on. In this regard QLGC might be a better candidate to consider a long position.